Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency: a study protocol for a multicentre, randomised, double-blinded, placebo-controlled clinical trial on health-related quality of life in patients with polymyalgia rheumatica/giant cell arteritis on low-dose prednisolone treatment (the RESCUE study) Authors: Stina Willemoes Borresen, Simon Bøggild Hansen, Hajir Al-Jorani, Randi Tei, Anja Fenger Dreyer, Victor Brun Boesen, Lise Sofie Bislev, Nanna Thurmann Jørgensen, Richard Christian Jensen, Marie Louise Lund Bjergstrøm, Louise Lehmann Christensen, Jelena Skaaning Stankovic Frederiksen, Dorte Glintborg, Jakob Bue Bjorner, Ulla Feldt-Rasmussen, Jens Otto Lunde Jorgensen, Marianne Skovsager Andersen, Marianne Klose Published: 2026 ABSTRACT AbstractIntroductionPatients on low-dose prednisolone may develop adrenal insufficiency causing reduced health-related quality of life (HRQoL) and increased risk of adrenal crisis. This study examines whether supplemental hydrocortisone during mild to moderate stress improves HRQoL in patients with polymyalgia rheumatica/giant cell arteritis (PMR/GCA) with adrenal insufficiency on low-dose prednisolone.Methods and analysisA multicentre, randomised, double-blinded, placebo-controlled, clinical trial including patients with PMR/GCA receiving ongoing prednisolone ≤5 mg/day. Eligible patients undergo an adrenocorticotropic hormone (ACTH) test, and 250 patients with a stimulated cortisol<420 nmol/L (biochemical adrenal insufficiency) are randomised 1:1 to supplemental hydrocortisone or placebo during mild to moderate stress (‘sick-days’) for 6 months or until daily prednisolone is stopped. The goal is 200 patients completing ≥3 months intervention period. Patients continue prednisolone tapering according to PMR/GCA guidelines. In the event of severe stress (risk of adrenal crisis), patients receive open-label hydrocortisone treatment. 95 patients with stimulated cortisol ≥420 nmol/L serve as control group. The primary outcome is HRQoL measured as fatigue using ecological momentary assessments (EMA) of the General Fatigue scale from the Multidimensional Fatigue Inventory-20, five times daily in situations of stress (‘sick-days’). EMA will be administered via a smartphone application ‘EMA live’. Differences in mean fatigue scores during sick-days between hydrocortisone and placebo will be analysed using mixed models for repeated measures. Secondary outcomes include daily smartphone-based symptom reporting, additional HRQoL questionnaires, adrenal crises, adverse effects from glucocorticoid excess, serial ACTH tests and biomarkers of adrenal insufficiency.Ethics and disseminationThe study is approved by the Ethics Committee of the Capital Region of Denmark and the Danish Medicines Agency. Recruitment began June 2022. The last patient’s last visit is expected in 2026. Results will be disseminated via peer-reviewed publication and conference presentations.Trial registration numbersEudraCT:2021-002528-18, CTIS:2024-518272-30-00, NCT05435781. STRENGTHS AND LIMITATIONS OF THIS STUDY Multicentre, randomised, double-blind, placebo-controlled trial design minimises risk of bias. Multicentre, randomised, double-blind, placebo-controlled trial design minimises risk of bias. The ‘EMA live’ smartphone-based ecological momentary assessments enable high-frequency real-time symptom reporting in daily life. The ‘EMA live’ smartphone-based ecological momentary assessments enable high-frequency real-time symptom reporting in daily life. Automated intensification of fatigue assessments during stress captures symptom variation in clinically relevant situations with minimal patient burden. Automated intensification of fatigue assessments during stress captures symptom variation in clinically relevant situations with minimal patient burden. Outcomes include predefined measures of both adrenal insufficiency and glucocorticoid excess. Outcomes include predefined measures of both adrenal insufficiency and glucocorticoid excess. The study is not powered to detect differences in treatment effect across varying degrees of adrenal insufficiency. The study is not powered to detect differences in treatment effect across varying degrees of adrenal insufficiency. Introduction Glucocorticoids are widely used to treat inflammatory and autoimmune diseases but can suppress the hypothalamic–pituitary–adrenal (HPA) axis and induce central adrenal insufficiency.1 At any given time, 0.5%–3% of the Western population are treated with systemic glucocorticoids2 and a meta-analysis indicate that up to half of these patients develop glucocorticoid-induced adrenal insufficiency.3 Even low-dose prednisolone (5 mg/day) is associated with an impaired response to adrenal function tests in more than one-third of long-term users.4 5 Cortisol is essential for survival and acute adrenal insufficiency can be fatal if left untreated, whereas glucocorticoid excess contributes to cardiovascular disease, osteoporosis, diabetes and infections.6 7 Correct diagnosis and appropriate management of adrenal insufficiency is therefore important. The daily production rate of cortisol during basal conditions is approximately 10 mg/day, which can be covered by an oral intake of 15–25 mg hydrocortisone (=3–5 mg prednisolone),8 but cortisol secretion increases markedly during stress.912 Patients tapering prednisolone below this physiological threshold may fail to mobilise an adequate stress response and thereby risk symptomatic adrenal insufficiency. To alleviate this, the international guideline recommends supplemental glucocorticoid during mild-moderate illness for patients on <10 mg prednisolone daily, unless recent testing excludes adrenal insufficiency.13 Decisions regarding hydrocortisone treatment are complicated by the fact that glucocorticoid-induced adrenal insufficiency represents a continuum of HPA-axis impairment and varying disease severity. Moreover, the nonspecific adrenal insufficiency symptoms often overlap with those of prednisolone-treated conditions, like polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) and with steroid withdrawal symptoms.14 15 Misattribution of adrenal insufficiency symptoms to underlying disease may contribute to reluctance in tapering prednisolone in PMR/GCA.4 16 17 Administration of glucocorticoid stress doses when needed may relieve adrenal insufficiency symptoms, prevent adrenal crises and may even improve prednisolone tapering success by preventing symptomatic setbacks during periods of stress.1719 However, repetitive hydrocortisone stress doses could also delay adrenal recovery and contribute to the clinical manifestations of glucocorticoid excess. No evidence-based data exist for the proper management of glucocorticoid-induced adrenal insufficiency. We therefore conduct the first double-blinded, randomised, placebo-controlled trial in patients on low-dose prednisolone with confirmed adrenal insufficiency to determine the effect of supplemental hydrocortisone on health-related quality of life (HRQoL). Methods and analyses Design and setting RESCUE is a randomised, double-blinded, placebo-controlled trial performed in three tertiary endocrine referral centres in Denmark: Odense University Hospital, Aarhus University Hospital and Copenhagen University Hospital, Rigshospitalet. Figure 1 presents study design. The study includes patients with PMR/GCA on ongoing low-dose prednisolone treatment, defined as ≤5 mg/day. Eligible patients undergo a standard adrenocorticotropic hormone (ACTH) test and 250 patients with a stimulated cortisol concentration <420 nmol/L (biochemical adrenal insufficiency) will be randomised to either placebo or hydrocortisone supplemental doses during mild to moderate illness and stress, also defined as ‘sick-days’ (figure 2). Prednisolone treatment is not part of the study intervention; tapering is managed by the treating rheumatologist in accordance with current guidelines.20 21 RESCUE lasts 6 months or until prednisolone is discontinued. Patients withdrawing before 3 months will be replaced with the same randomisation code. If PMR/GCA flares require prednisolone >5 mg/day, the study period is prolonged accordingly until a maximum of 9 months. Overall study design in RESCUE. Eligible patients with PMR/GCA treated with ≤5 mg prednisolone/day will undergo an ACTH test and 250 patients with adrenal insufficiency (30-minute P-cortisol <420 nmol/L) will be randomised to hydrocortisone or placebo stress doses during mild to moderate intercurrent illness and stress. Ninety-five patients with normal adrenal function will be included as a reference group (no intervention and follow-up on key-outcomes only, see table 1). ACTH, adrenocorticotropic hormone; GCA, giant cell arteritis; PMR, polymyalgia rheumatica; RCT, randomised controlled trial. Table 1Timing of data collectionVariableInformation visitVisit 1(Screening)Visit 2(Baseline)Extra visits(X1+X2)Visit 3(telephone, 1 week)Visit 4(telephone, 1 month)Visit 5(3 months)Visit 6(6 months)Informed consentXACTH test, including salivary samplesXX*X*(RCT only)X(RCT only)Start-up EMA live smartphone app†XXHRQoL questionnaires (AddiQoL36, SF-36v2, PLSF, Cushing QoL)XXX(RCT only)Blood samplesXXX*X*(RCT only)X(RCT only)Medical history, including prednisolone historyXXXXClinical examinationXX(RCT only)24-hour urine samplesXX(RCT only)Automated office blood pressureXX(RCT only)DXA scan including whole-body and regional fat mass, and VFAXX(RCT only)Bedside muscle function testsXX(RCT only)Randomisation, start of study medicationX(RCT only)X(RCT only)Information on principles for stress dose useX(RCT only)X(RCT only)X(RCT only)X(RCT only)Recording of adverse events and reactionsX(RCT only)X(RCT only)X(RCT only)X(RCT only)*Only performed in a subgroup. †One version is installed at screening and changed at the baseline visit to the version that runs the rest of the study. Screening and control group versions refers to registration of stress rather than study medication use as the only difference. ACTH, adrenocorticotropic hormone; AddiQoL, Addison’s Disease specific Quality of Life Questionnaire; DXA, Dual-energy X-ray absorptiometry; EMA, ecological momentary assessment; HRQoL, health-related quality of life; PLSF, Patient Life Situation Form; QoL, quality of life; RCT, randomised controlled trial; SF-36v2, 36-Item Short Form Health Survey version 2; VFA, Vertebral Fracture Assessment. Timing of data collection Only performed in a subgroup. One version is installed at screening and changed at the baseline visit to the version that runs the rest of the study. Screening and control group versions refers to registration of stress rather than study medication use as the only difference. ACTH, adrenocorticotropic hormone; AddiQoL, Addison’s Disease specific Quality of Life Questionnaire; DXA, Dual-energy X-ray absorptiometry; EMA, ecological momentary assessment; HRQoL, health-related quality of life; PLSF, Patient Life Situation Form; QoL, quality of life; RCT, randomised controlled trial; SF-36v2, 36-Item Short Form Health Survey version 2; VFA, Vertebral Fracture Assessment. English translation of the patient guidelines for taking study medication during illness or stress. 1813 and 112, Danish emergency telephone numbers; EMA, ecological momentary assessment. Baseline HRQoL assessments are completed before patients are informed of ACTH test results to secure unbiased reporting. At randomisation, patients receive oral and written instructions on stress-dose use (figure 2). Follow-up phone calls after 1-week and 1-month ensure compliance and understanding, and patients are encouraged to contact study staff with questions between visits. A blinded mid-study (3 months) ACTH test is performed at one centre. Patients are instructed to pause prednisolone 1 day before the ACTH tests (last dose the day before the test) at screening, 3 months (blinded results) and 6 months. Forty consecutive patients, all on 5 mg/day prednisolone, will undergo two extra ACTH tests where prednisolone is paused 0 and 2 days before the test, respectively, to investigate the influence of the length of the prednisolone pause on ACTH test response. Control group: 95 patients with stimulated cortisol ≥420 nmol/L (normal adrenal function) will be used as a reference group. These patients will undergo screening and baseline examinations, 3 month’s reporting of stress and HRQoL, and 6 months follow-up through medical records on prednisolone treatment characteristics. Visit schedule and data collection are shown in table 1. Study population RESCUE includes patients aged ≥50 years (women must be postmenopausal) diagnosed with PMR, GCA or both. Patients must have received prednisolone treatment for ≥12 weeks with a daily prednisolone dose ≤5 mg for a minimum of 2 weeks prior to screening. Exclusion criteria: Known primary or secondary adrenal insufficiency, endogenous Cushing syndrome, allergy towards study medication or severe comorbidity (New York Heart Association heart failure class IV, chronic kidney disease stage 4–5, cirrhosis, active cancer, severe immune deficiency, psychiatric disease requiring treatment by a psychiatric department (for affective disorders only if <1 year before study entry)); alcohol consumption >21 units/week; planned major surgery during the study period; systemic oestrogen treatment (discontinued <1 month before inclusion); treatment with strong CYP3A4 inhibitors or inducers; use of other glucocorticoid formulations: inhaled corticosteroids, intraarticular or intramuscular injections, steroid creams European steroid group IV–V used in the genital area; and inability to provide written informed consent. Recruitment Patients are included from 11 Danish departments of rheumatology and with advertisement in private rheumatology practice and on hospital websites and social media. At the departments of rheumatology, potential participants are identified by affiliated medical doctors or delegates. All patients with PMR/GCA receive prednisolone treatment and are thus potential participants and are identified through a search for the relevant diagnosis codes in the electronic medical record system. A pre-screening of patients for inclusion and exclusion criteria based on medical records is performed. Potential participants are invited to an information visit via a letter and a subsequent phone call. Investigators (medical doctors only) with documented good clinical practice (GCP) and protocol training at the endocrine departments obtain written informed consent (online supplemental file 1) before any trial-related activity. Intervention, blinding and safety Intervention and blinding Patients with an ACTH-stimulated plasma-cortisol (P-cortisol) <420 nmol/L are randomised 1:1 to hydrocortisone (10 mg tablets) or placebo ‘stress doses’ in situations of mild–moderate physical or emotional stress. At study initiation in 2022, routine adrenal testing and stress-dose advice were not standard for patients tapering prednisolone. Placebo therefore represents standard of care but with safety precautions in situations of severe stress (see safety). The trial is conducted in a double-blinded manner, with blinding of patients, study personnel and statisticians (see statistics). Patients receive standardised oral and written information about when and how long to add study medication stress doses and when and how to seek medical advice (figure 2). Patients record illness, stress and use of study medication daily through ‘end-of-day’ study smartphone app entries but can also initiate registrations independently at any time. Control patients do not take study medication but record illness, stress and HRQoL identically to the randomised controlled trial (RCT) group (3 months only). Patients’ understanding of and adherence to intervention including safety precautions is addressed with the follow-up phone calls. In addition, the sponsor site overviews the primary outcome by generating monthly reports on response rates and all patients with response rates <65% are contacted by phone to solve any questions or technical app issues. Safety The trial protocol covers only situations of mild–moderate stress. Patients are carefully instructed that in case of severe stress (eg, suspected adrenal crisis, persistent vomiting/diarrhoea, severe intercurrent illness or surgery) they cannot rely on study medication stress doses but must seek emergency medical care for treatment with open-label glucocorticoid in accordance with standard clinical practice for adrenal insufficiency. This is clearly marked in patients’ written and oral information (figure 2) and in electronic medical records. All patients are provided with a steroid emergency card22 and open label hydrocortisone tablets. Direct telephone contact with the study team is available 24/7. Randomisation, allocation and unblinding The 1:1 randomisation to hydrocortisone or placebo is stratified by degree of adrenal suppression (ACTH stimulated cortisol <200 vs 200–419 nmol/L) and concomitant treatment with tocilizumab (yes/no, as it may affect glucocorticoid exposure23), using randomly permuted blocks within each study centre. The random allocation sequence was generated using a computerised random number generator (www.sealedenvelope.com) and implemented in the data management system Research Electronic Data Capture (REDCap) (www.project-redcap.org) that assigns patients a unique randomisation code. Allocation concealment is ensured through pre-labelled medication containers with unique label numbers that do not reveal treatment assignment. Only the pharmacy and unblinded study staff, not otherwise involved in the trial, have access to the allocation sequence and medication list. At randomisation, an unblinded staff member links the assigned code to the correct pre-labelled medication, documents both code and label, and a second unblinded staff member verifies correctness before drug dispensation. The process is monitored by an unblinded GCP monitor. Unblinding of a patient’s allocation is possible through phone contact to the pharmacy (24-hour service), but as patients are treated with open-label glucocorticoid in situations of severe stress/adrenal crises no acute need for unblinding is expected. Unblinding will be performed by site primary investigator, and other members of the study group will remain blinded. Study medication Hydrocortisone 10 mg tablets are manufactured by Orion Pharma Denmark, identical placebo by Glostrup Pharmacy (CVR no. DK37302872). Production, packing, blinding, labelling, numbering and shipment to sites of study medicine are done by the Glostrup Pharmacy according to Good Manufacturing Practice for medicinal products. Outcomes Primary outcome The General Fatigue scale from the Multidimensional Fatigue Inventory (MFI-20), assessed five times daily through ecological momentary assessments (EMA) in situations of stress (‘sick-days’). The General Fatigue scale from the Multidimensional Fatigue Inventory (MFI-20), assessed five times daily through ecological momentary assessments (EMA) in situations of stress (‘sick-days’). Key secondary outcomes Daily end-of-day smartphone-based symptom reporting. Daily end-of-day smartphone-based symptom reporting. Questionnaire-based HRQoL measures: 36-Item Short Form Health Survey version 2 (SF-36v2), Addison’s Disease specific Quality of Life Questionnaire (AddiQoL-30) administered at baseline, 3 and 6 months. Questionnaire-based HRQoL measures: 36-Item Short Form Health Survey version 2 (SF-36v2), Addison’s Disease specific Quality of Life Questionnaire (AddiQoL-30) administered at baseline, 3 and 6 months. PMR/GCA treatment characteristics: time from 5 mg prednisolone to withdrawal; accumulated glucocorticoid dose; total duration of prednisolone therapy. PMR/GCA treatment characteristics: time from 5 mg prednisolone to withdrawal; accumulated glucocorticoid dose; total duration of prednisolone therapy. Incidence and causes of ‘sick-days’. Incidence and causes of ‘sick-days’. Influence of the length of the prednisolone pause (0 vs 1 vs 2 days) on ACTH test outcome. Influence of the length of the prednisolone pause (0 vs 1 vs 2 days) on ACTH test outcome. Safety outcomes Incidence of adrenal crisis. Incidence of adrenal crisis. Cushingoid features (assessed at baseline and end-of-study):Body composition and bone healthCardiovascular healthGlucose homeostasisPhysical functionPatient-reported: CushingQoL, Single-item Sleep Quality Scale and International Physical Activity Questionnaire. Cushingoid features (assessed at baseline and end-of-study): Body composition and bone health Body composition and bone health Cardiovascular health Cardiovascular health Glucose homeostasis Glucose homeostasis Physical function Physical function Patient-reported: CushingQoL, Single-item Sleep Quality Scale and International Physical Activity Questionnaire. Patient-reported: CushingQoL, Single-item Sleep Quality Scale and International Physical Activity Questionnaire. Exploratory outcomes PMR/GCA activity: number of flares/relapses during study period. PMR/GCA activity: number of flares/relapses during study period. Integrated cortisol status: ACTH test normalisation; 24-hour urine cortisol/cortisone; salivary cortisol/cortisone; cortisol binding globulin and Free Cortisol Index; circulating biomarkers of glucocorticoid effects including glucocorticoid bioactivity and metabolomics. Integrated cortisol status: ACTH test normalisation; 24-hour urine cortisol/cortisone; salivary cortisol/cortisone; cortisol binding globulin and Free Cortisol Index; circulating biomarkers of glucocorticoid effects including glucocorticoid bioactivity and metabolomics. Explanation of outcome measures Outcome measures and their timing are listed in table 1. Smartphone based HRQoL assessments Fatigue is a predominant complaint in adrenal insufficiency,2427 which can be measured using the MFI-2028 for which we adapted and validated a smartphone-based version.29 30 Using EMA,30 MFI-20 data are collected multiple times daily to capture real-time fatigue in the patients’ natural environments. We previously applied this approach to detect treatment-related fatigue changes in secondary adrenal insufficiency.29 30 For the current study, we further developed and validated the ‘EMA live’ app to feature reporting of intercurrent illness, stress, study medication use and end-of-day symptom monitoring. The app follows state-of-the-art standards for electronic EMA instruments.3133 This includes individually adjustable diurnal rhythm, repeated auditory alerts, possibility to postpone data entry for up to 1 hour, a ‘do-not-disturb’ function and time stamping of data entries. The ‘EMA live’ application is integrated with the trial management system REDCap securing automatic data transfer to hospital servers via an encrypted connection, where data completeness can be surveyed in real time. The system is approved by regional authorities (Legal approval no P-2021-891). EMA of fatigue Patient reports of stress or illness requiring study medication will automatically trigger a 3-day EMA fatigue assessment period. During this period, patients will be prompted by the app five times daily at semi-randomised time points to answer the four momentary MFI-20, General Fatigue items. The five daily assessments allow investigation of variation in fatigue both between and within days. To reduce response burden, only the four items regarding General Fatigue are used, chosen based on scale validation analysis on data from the PlenadrEMA study.29 If patients report additional illness/stress during the 3-day assessment period, the period will be further extended to 2 days after the last ‘sick-day’. Additionally, a 3-day EMA assessment period is applied monthly in illness/stress-free periods as a reference. Daily ‘end-of-day’ app-facilitated symptom assessments Every day, 1 hour before the patient’s reported normal bedtime, the ‘EMA live’ app prompts ‘end-of-day’ questions about symptoms and stress. The patients are asked about four symptoms (fatigue, dizziness, nausea and feeling unwell) previously identified as the most frequent and most significant indicators of the need for supplemental hydrocortisone in patients with long-standing glucocorticoid-induced adrenal insufficiency.34 The questions originate from the Danish version of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events,35 with the recall period adapted with permission from 7 days to 24 hours to fit daily ‘end-of-day’ assessments. Usability testing in patients led to slight rephrasing of one of the questions before study initiation. The ‘end-of-day’ symptom assessments follow the Symptom Tracking and Reporting system principle36; if a symptom worsens by ≥2 points compared with the previous day, the patient is notified that an increase in symptom grading is detected and asked whether she/he is unwell in a way to consider if study medication is required. The question about illness, injury or stress (‘sick days’) is a simple ‘within the last 24 hours, have you experienced any illness, injury or stress? A positive answer triggers questions specifying the cause and study medication use. At enrolment, the study staff will educate patients to use the ‘EMA live’ app followed by a 5-day baseline assessment and technology-adaptation phase before repeated onsite training, randomisation and intervention. Other HRQoL assessments Three times during the study (baseline, 3 months, 6 months), patients are asked to complete the generic and disease-specific questionnaires SF-36v2, AddiQoL-30, CushingQoL, Single item Sleep Quality Scale and International Physical Activity Questionnaire. ACTH test After 15 min of seated rest, P-cortisol is measured before and 30 min after 250 µg ACTH (Synacthen) injection. Patients are instructed to pause prednisolone 1 day before the test (last dose the day before the test), and the test is scheduled between 8:00 and 16:00, as 30-minute ACTH test responses are not affected by diurnal variation.37 38 Adrenal insufficiency is defined as 30-minute P-cortisol <420 nmol/L according to local validation.39 Saliva cortisol and cortisone are measured before and 30 min after ACTH injection. Samples for ACTH measurements are drawn at baseline and end-of-study. Prednisolone pause before ACTH test 40 patients will undergo two extra ACTH tests after 0 and 2 days of prednisolone pause, meaning last prednisolone dose taken on the day of the test or 2 days before the test, respectively. The exact number of hours of prednisolone pause is registered. For these patients, samples for ACTH measurements are drawn at each ACTH test, before ACTH injection. Prednisolone cross-reactivity in the Roche Elecsys cortisol II immunoassay at different timepoints (hours) since last prednisolone dose is determined by measuring plasma-prednisolone concentrations with LC-MS and cortisol concentrations with both LC-MS and Roche Elecsys cortisol II immunoassay. Medical history Data include chronic comorbidities (Charlson Comorbidity Index), PMR/GCA diagnosis, concomitant medication and supplements intake, alcohol and tobacco consumption, and history of fractures. The history of prednisolone treatment is obtained from patients’ medical records and patient interview and registered in detail for the period 6 months before the study and during the study. Adrenal crisis Adrenal crises and severity hereof are defined as previously described.24 40 Incidence and severity of adrenal crises, including information on hospitalisations, number of sick days, diagnoses and therapy, will be assessed through patient interview and medical records. Blood pressure Blood pressure is measured after a 5-minute rest period and then three times at 1-minute intervals first with (office blood pressure) then without an observer in the room (automated office blood pressure). Body composition and bone quality Height, weight, body mass index and waist and hip circumference are recorded. Dual X-ray absorptiometry is used to measure whole body lean body mass, fat mass and bone density. Vertebral fracture assessment is performed at two centres. Timed Up and Go The Timed Up and Go Test measures physical performance and coordination by measuring the time to stand up, walk 3 m in a straight line, and immediately return to the chair.41 Handgrip strength Handgrip strength is measured using a hydraulic hand dynamometer (JAMAR) with the patient seated, elbow flexed at 90°, and wrist in neutral position. Three trials are performed with the dominant hand; mean and peak values are recorded. Short physical performance battery including chair rising test The short physical performance battery is bedside measures that combines the results of walking speed, chair stand and balance tests.42 Blood and urine samples In addition to ACTH test samples, fasting morning blood samples are drawn after 15-minute seated rest at baseline and end of study. Planned biochemical analyses include hormones, glycaemic, bone, cardiovascular, inflammation, kidney, liver and haematology markers, biomarkers for adrenal insufficiency, glucocorticoid sensitivity and action, and biobank samples. Urine sampled for 24 hours for cortisol and cortisone analysis. Statistics Power calculations The primary outcome is EMA-based MFI-20 General Fatigue during stress. Power analyses were informed by data from the PlenadrEMA study, which compared conventional and dual-release hydrocortisone in patients with secondary adrenal insufficiency.29 The RESCUE study is designed to detect an improvement of 1.35 points—approximately 50% greater than in PlenadrEMA—reflecting that RESCUE compares hydrocortisone with placebo rather than two active formulations. Assuming eight ‘sick-days’ per patient, as previously recorded in adrenal insufficiency,29 43 a between- and within-patient variance of 10 points², and a 5% significance level, 200 patients provide 82% power. Accounting for a 20% dropout rate, 250 patients (125 per group) will be recruited. We expect to screen 1000 patients with an ACTH test to identify 250 patients with an insufficient test response for the RCT group.3 17 For key secondary outcomes (1) Difference in end-of-day symptoms: Based on PlenadrEMA single symptom data, 100 patients provide 80% power (p=0.05) and (2) ACTH test (1-day vs 2-day prednisolone pause): Assuming a 100 nmol/L mean difference (SD=140), 40 paired patients yield 80% power (p=0.05). Data analysis plan Data will be analysed using parametric or non-parametric statistics as appropriate. Baseline differences between hydrocortisone and placebo groups will be evaluated with t-tests or Wilcoxon rank-sum tests for continuous variables and χ² tests for categorical variables. The primary analysis compares mean EMA-MFI-20 General Fatigue during stress periods between treatment groups, using mixed models for repeated measures. Models will be presented unadjusted and adjusted for age, sex, prednisolone dose, degree of adrenal suppression and underlying disease (PMR/GCA). Secondary analyses include diurnal fatigue profiles (within-day variation) across all stress periods and other treatment effects analysed as Δ-values (post–pre) by t-tests or Wilcoxon tests. For the repeated ACTH tests, cortisol responses after 0, 1 and 2-day prednisolone pauses will be compared using repeated-measures ANOVA and paired t-tests (key comparison: 1 vs 2 days). Analyses are two-sided (p<0.05) and performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) or R. Missing data will be handled by complete case analysis or mean imputation for HRQoL questionnaires. All analyses will follow the prespecified statistical analysis plan after database lock. Treatment codes (group A/B) remain blinded until completion and approval of the primary analysis. Data collection and management Study data are collected and managed electronically in REDCap,44 hosted by the Capital Region of Denmark and compliant with Danish Data Protection Agency and General Data Protection Regulation. Data are filed by patient number, pseudonymised, and stored securely for 25 years. Each site maintains an access-controlled local drive for supplementary study files. Approval to access medical records was granted by the Regional Ethics Committee in accordance with Danish law. The sponsor site ensures study quality through development of standard operating procedures (SOPs), joint training, and regular meetings. Study personnel (nurses and physicians) act under the Danish Health Act and receive documented protocol training. A limited number of investigators perform all patient visits to ensure consistency. Laboratory analyses are conducted at accredited hospital laboratories using validated assays. The sponsor issues monthly reports on ‘EMA live’ app compliance, and patients with <65% response rates are contacted to ensure data completeness. Adverse event reporting All adverse events (AEs), serious AEs and suspected unexpected serious adverse reactions will be recorded and reported in accordance with International Council for Harmonisation Good Clinical Practice and national regulations to the Danish Medicines Agency and ethics committee. Events related to cortisol deficiency or excess are systematically monitored as predefined outcomes. Monitoring Data and study monitoring is performed by the regional GCP units in Denmark, and the trial is part of the GCP audit programme. Authorised monitors and regulators have direct access to source data. Study status Recruitment began in June 2022, with the last patient’s last visit expected in June 2026. Primary analyses will follow, with main results expected within 12 months. Patient and public involvement A patient advisory group, including representatives from the Danish Addisonian Association and individuals with adrenal insufficiency and rheumatic disease, contributed to the protocol’s design. Patient feedback informed outcome selection, feasibility and safety. Symptom selection for the EMA Live app was based on a dedicated study of symptoms34 supplemented by usability testing (unpublished). Ethics and dissemination RESCUE is approved by relevant authorities (Denmark’s Capital Region Ethics Committee approval number H-21041930) and conducted in accordance with the Declaration of Helsinki and GCP. RESCUE is registered with EudraCT: 2021-002528-18, CTIS: 2024-518272-30-00, ClinicalTrials.gov: NCT05435781. Safety precautions are included in the study protocol and placebo reflects standard care. Patients are insured under the Danish healthcare system. Results will be published in peer-reviewed journals according to the International Committee of Medical Journal Editors recommendations and presented at scientific meetings, regardless of outcome. Discussion RESCUE will provide the first evidence-based foundation for stress-dose management in glucocorticoid-induced adrenal insufficiency. Results are expected to generate evidence to guide future clinical practice and improve the quality of care for patients receiving long-term glucocorticoid therapy across medical specialties. Placebo represents current standard of care, as adrenal testing and routine stress-dosing remain non-standard in many non-endocrine settings, including in Denmark, despite recent international guidelines.13 45 There is limited evidence supporting routine stress-dosing in non-hospitalised patients.13 RESCUE therefore addresses an important evidence gap. Participant safety is ensured through continued prednisolone therapy and a predefined rescue protocol for severe stress or impending adrenal crisis. Also, since patients have preserved mineralocorticoid function and often partial glucocorticoid deficiency they will often not develop adrenal crises as rapidly as patients with primary adrenal insufficiency. Because symptoms of intercurrent illness and adrenal insufficiency overlap, a randomised placebo-controlled design—including a reference group with intact HPA-axis function—is required to isolate the symptomatic effects of adrenal suppression. Adrenal crises will also be recorded independently to detect potential preventive effects of stress-dosing even if subjective HRQoL outcomes remain unchanged. Since glucocorticoid-induced adrenal insufficiency spans a continuum of HPA-axis suppression, treatment needs may vary accordingly. Although RESCUE is not powered for subgroup analyses by degree of adrenal suppression, patient randomisation is stratified accordingly. The cut-off for severe adrenal insufficiency is unvalidated and used solely to balance randomisation. Measures of glucocorticoid excess are included to document the overall balance of glucocorticoid exposure. Occasional stress doses are not expected to cause clinically relevant manifestations of glucocorticoid excess. If the intervention group achieves a more rapid prednisolone tapering by avoiding symptom ‘setbacks’ during stress, their total cumulative glucocorticoid burden might be lower than the placebo group. PMR and GCA were selected as model diseases due to uniform long-term prednisolone exposure and standardised tapering. Most patients discontinue prednisolone within 1–3 years (with expected 18–26 weeks with ≤5 mg/day20 21), yet relapses occur in ~50% prolonging the treatment.4648 To reflect real-life conditions and avoid excessive dropouts, the protocol allows study-period extensions following temporary prednisolone increases above 5 mg/day. ‘EMA live’ data collected during such periods will be excluded from analyses. The ‘EMA live’ smartphone-based fatigue assessments capture real-time symptom variation during unpredictable stress events, building on the group’s prior work with validated questionnaire development and adaptation into momentary smartphone app-based instruments.294951 Supplementary material